Payment overview · 2025
General Payments
$945.82
32 reported records · 12 companies
Healthcare provider profile · identity verified
Joonhye Kook
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FORT LEE, NJ · NPI 1639576325
Verified facts
What the public records show
CMS Open Payments records show Joonhye Kook received $945.82 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Ozempic, Rexulti, Rybelsus, Shingrix, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $307.75 | 32.5% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $142.49 | 15.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.84 | 12.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $109.08 | 11.5% | 7 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $100.84 | 10.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.52 | 6.5% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.64 | 2.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.42 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.21 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.71 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.58 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.74 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $945.82 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $183.35 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $182.75 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $142.49 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $100.84 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.09 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.09 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.07 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.07 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 166 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 160 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 20 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 184 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
166 | 44 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
160 | 37 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
184 | 31 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
115 | 78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1100 | 367 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 227 |
| Losartan Potassium | Losartan Potassium | 580 | 186 |
| Vascepa | Icosapent Ethyl | 574 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 377 | 124 |
| Metformin Hcl | Metformin Hcl | 325 | 110 |
| Lisinopril | Lisinopril | 217 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 77 |
| Lidocaine | Lidocaine | 203 | 51 |
| Zenpep | Lipase/Protease/Amylase | 184 | 31 |
| Alendronate Sodium | Alendronate Sodium | 166 | 60 |
| Creon | Lipase/Protease/Amylase | 166 | 44 |
| Linzess | Linaclotide | 160 | 37 |
| Omeprazole | Omeprazole | 150 | 60 |
| Eliquis | Apixaban | 140 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 56 |
| Metformin Hcl Er | Metformin Hcl | 135 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 40 |
| Jardiance | Empagliflozin | 122 | 32 |
| Trazodone Hcl | Trazodone Hcl | 120 | 38 |
| Finasteride | Finasteride | 119 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 39 |
| Gabapentin | Gabapentin | 117 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 32 |
| Famotidine | Famotidine | 115 | 48 |
| Prolia | Denosumab | 115 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 30 |
| Donepezil Hcl | Donepezil Hcl | 110 | 33 |
| Mirtazapine | Mirtazapine | 110 | 33 |
| Farxiga | Dapagliflozin Propanediol | 103 | 30 |
| Januvia | Sitagliptin Phosphate | 98 | 24 |
| Carvedilol | Carvedilol | 95 | 27 |
| Ezetimibe | Ezetimibe | 93 | 33 |
| Ozempic | Semaglutide | 91 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 24 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 81 | 18 |
| Allopurinol | Allopurinol | 79 | 22 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 69 | 20 |
| Sertraline Hcl | Sertraline Hcl | 67 | 26 |
| Glimepiride | Glimepiride | 62 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 19 |
| Azithromycin | Azithromycin | 59 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 29 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Restasis | Cyclosporine | 56 | 14 |
| Montelukast Sodium | Montelukast Sodium | 52 | 17 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 52 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 49 | 31 |
| Pregabalin | Pregabalin | 49 | 13 |
| Simvastatin | Simvastatin | 49 | 18 |
| Azelastine Hcl | Azelastine Hcl | 47 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 13 |
| Ammonium Lactate | Ammonium Lactate | 46 | 19 |
| Meloxicam | Meloxicam | 45 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 15 |
| Furosemide | Furosemide | 44 | 21 |
| Atenolol | Atenolol | 43 | 13 |
| Benazepril Hcl | Benazepril Hcl | 43 | 13 |
| Rybelsus | Semaglutide | 43 | suppressed |
| Irbesartan | Irbesartan | 42 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 39 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 14 |
| Celecoxib | Celecoxib | 36 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 32 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 34 | suppressed |
| Colchicine | Colchicine | 31 | 12 |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Cyclosporine | Cyclosporine | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 25 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 27 | 13 |
| Ztlido | Lidocaine | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Valsartan | Valsartan | 26 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 16 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 14 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | 11 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Prednisone | Prednisone | 17 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $945.82 · 32 records | ABBVIE INC. | CREON, EVENITY, JARDIANCE, LEQVIO, LINZESS, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, Wegovy, XIFAXAN, ZENPEP, ZORYVE, ZTLido | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error